Merck KGaA: raises targets for 2024

(CercleFinance.com) - Thanks to good sales performance in Healthcare and Electronics, group Q2 2024 sales rose by 1.
7% organically. Overall, group sales rose by 0.9% to E5,352m.

EBITDA was down 0.8% organically to E1.5bn, against a high comparison basis.

Healthcare and Electronics recorded organic sales growth. AI semiconductor materials market reaches inflection point. Process Solutions order intake continues to improve sequentially and y-o-y, the group says.

Merck raises its targets for 2024 and for the Healthcare and Electronics business sectors. The group expects net sales of E20.7bn to E22.1bn and organic growth of +2% to +5% (previously: E20.6bn to E22.1bn; organic growth of +1% to +5%).

EBITDA should be in the range of E5.8bn to E6.4bn, with organic growth of +4% to +10% (previously: E5.7bn to E6.3bn; organic growth of +1% to +7%). EPS is now expected to be between E8.20 and E9.30 (previously: E8.05 to E9.10).


Copyright (c) 2024 CercleFinance.com. All rights reserved.